235 The role of the MR 7 REFERENCES 1. Inaba H, Pui C-H: Glucocorticoid use in acute lymphoblastic leukaemia. The Lancet Oncology 11:1096-1106, 2010 2. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-78, 2006 3. Snelling CE, Donohue WL, Laski B, et al: Pituitary adrenocorticotropic hormone (ACTH) and 11-dehydro-17 hydroxy corticosterone (cortisone) therapy in the leukemias and lymphomas of children. Pediatrics 8:26-33, 1951 4. Veerman AJ, Kamps WA, van den Berg H, et al: Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 10:957-66, 2009 5. Quddus FF, Leventhal BG, Boyett JM, et al: Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: a Pediatric Oncology Group Study. Cancer Res 45:6482-6, 1985 6. Liu H, Li Z, Qiu F, et al: Association Between NR3C1 Mutations and Glucocorticoid Resistance in Children With Acute Lymphoblastic Leukemia. Front Pharmacol 12:634956, 2021 7. van der Zwet JCG, Smits W, Buijs-Gladdines J, et al: Recurrent NR3C1 Aberrations at First Diagnosis Relate to Steroid Resistance in Pediatric T-Cell Acute Lymphoblastic Leukemia Patients. Hemasphere 5:e513, 2021 8. Warris LT, van den Heuvel-Eibrink MM, Aries IM, et al: Hydrocortisone does not influence glucocorticoid sensitivity of acute lymphoblastic leukemia cells. Haematologica 100:e137-9, 2015 9. Grossmann C, Scholz T, Rochel M, et al: Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol 151:397-406, 2004 10. Lustig R: Corticosteroid replacement therapy, in Lin ANP, S. A. (ed): Principles of Corticosteroid Therapy. New York, Arnold, 2002, pp 205-220 11. Warris LT, van den Heuvel-Eibrink MM, Aarsen FK, et al: Hydrocortisone as an Intervention for Dexamethasone-Induced Adverse Effects in Pediatric Patients With Acute Lymphoblastic Leukemia: Results of a Double-Blind, Randomized Controlled Trial. J Clin Oncol 34:2287-93, 2016 12. van der Zwet JCG, Buijs-Gladdines J, Cordo V, et al: MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. Leukemia 35:3394-3405, 2021 13. Hehir-Kwa JY, Koudijs MJ, Verwiel ETP, et al: Improved Gene Fusion Detection in Childhood Cancer Diagnostics Using RNA Sequencing. JCO Precis Oncol 6:e2000504, 2022 14. Dobin A, Davis CA, Schlesinger F, et al: STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15-21, 2013 15. Lu J, Hu F, Zhou Y: NR3C2-Related Transcriptome Profile and Clinical Outcome in Invasive Breast Carcinoma. Biomed Res Int 2021:9025481, 2021 16. den Boer ML, Cario G, Moorman AV, et al: Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematol 8:e55-e66, 2021 17. Abd ElHafeez S, Torino C, D’Arrigo G, et al: An overview on standard statistical methods for assessing exposure-outcome link in survival analysis (Part II): the Kaplan-Meier analysis and the Cox regression method. Aging Clin Exp Res 24:203-6, 2012
RkJQdWJsaXNoZXIy MTk4NDMw